Breast Care最新文献

{"title":"Clinicopathological Factors Affecting Positive Margins after Breast-Conserving Surgery: A Comparative Study of Low- and High-Volume Hospitals.","authors":"Seher Makineli, Sofie A M Gernaat, Milan C Richir, Wouter B Veldhuis, Liesbeth M Veenendaal, Maaike R Moman, Patrick I Ferdinandus, Menno R Vriens, Paul J van Diest, Wies Maarse, Arjen J Witkamp","doi":"10.1159/000544904","DOIUrl":"10.1159/000544904","url":null,"abstract":"<p><strong>Purpose: </strong>Positive margins after breast-conserving surgery (BCS) are an important risk factor for local tumor recurrence and the need for re-excision in women with breast cancer. It remains unclear which factors collectively influence positive margins after BCS and whether the outcomes vary among hospitals. This study investigated the occurrence and risk factors of positive margins after BCS in women with breast cancer in two Dutch hospitals.</p><p><strong>Methods: </strong>Data were collected retrospectively from medical records of women who were diagnosed with newly invasive breast carcinoma or carcinoma in situ and underwent primary BCS between January 1, 2018 and December 31, 2020 in two Dutch hospitals.</p><p><strong>Results: </strong>A total of 423 cases (410 patients) were included, with a median age of 58 years (interquartile range 51-66). On average, the positive margin rate after BCS was 8.0%, which was significantly higher in the low-volume hospital (14.9%) than in the high-volume hospital (5.9%). Invasive lobular carcinoma (odds ratio [OR] = 4.97, confidence interval [CI] = 1.91-12.94), postoperative tumor size (OR = 1.07, CI = 1.03-1.11), low hospital volume (OR = 3.90, CI = 1.58-9.66), and lumpectomy size (OR = 0.97, CI = 0.94-1.00) were significantly associated with positive margins after BCS.</p><p><strong>Conclusion: </strong>Positive margin rate after BCS was low, with 8.0% among all cases and varied significantly between the hospitals. Patient-, tumor-, radiological-, and surgery-related factors may contribute to these variations. An optimized collaborative multidisciplinary approach to breast cancer care, particularly between radiologists and surgeons, should be strived to achieve improved oncological outcomes in women after BCS.</p>","PeriodicalId":9310,"journal":{"name":"Breast Care","volume":"20 4","pages":"238-247"},"PeriodicalIF":2.1,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12377799/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144943808","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Idiopathic Granulomatous Mastitis: A Consensus Report on Treatment and Follow-Up Approaches Based on the Turkish Clinical Classification.","authors":"Mustafa Emiroglu, Kenan Cetin, Kerim Bora Yilmaz, Mehmet Velidedeoglu, Sadullah Girgin, Alper Akcan, Ozgur Aytac, Murat Akın, Hande Koksal, Neslihan Cabioglu, Nuh Zafer Canturk, Bahadır Gulluoglu","doi":"10.1159/000544967","DOIUrl":"10.1159/000544967","url":null,"abstract":"<p><strong>Objective: </strong>The second consensus study on idiopathic granulomatous mastitis (IGM) aimed to establish treatment options based on the clinical classification proposed in the first consensus, standardize criteria for treatment discontinuation, and develop follow-up protocols.</p><p><strong>Method: </strong>A structured methodology, identical to the first consensus study, was employed. An 11-member working group of breast surgeons experienced in IGM from various clinics across the country was formed. The modified Delphi method was used, with a consensus threshold of 80% agreement.</p><p><strong>Results: </strong>Three voting rounds were conducted to develop the IGM treatment algorithm. In Round 1, observation was established as the first-line option for Type 1 disease (81%) and pregnancy/lactation cases (85%). Round 2 achieved consensus on systemic steroids (SS) as the first-line treatment for Type 3 cases (84%), combination therapies for resistant cases (82%), and reclassification of recurrent cases to guide treatment planning (94%). In Round 3, consensus was reached on the use of immunosuppressive therapy (IMT) for cases where steroids are contraindicated in Type 3 (81%), the use of IMT for resistant cases (93%), avoiding surgery as the first-line option for Type 1 cases (81%), and requiring complete clinical and radiological response before discontinuing treatment (81%). However, no consensus was reached on the first-line treatment for Type 2 disease.</p><p><strong>Conclusion: </strong>This consensus study successfully developed a treatment algorithm for IGM, prioritizing observation for Type 1 disease and cases involving pregnancy or lactation, and recommending systemic steroids (SS) and immunosuppressive therapies for Type 3 cases. The findings underscore the critical importance of achieving complete clinical and radiological remission before discontinuing treatment. However, the lack of consensus on the treatment of Type 2 disease highlights the need for further research into this challenging subtype.</p>","PeriodicalId":9310,"journal":{"name":"Breast Care","volume":"20 4","pages":"248-255"},"PeriodicalIF":2.1,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12377798/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144943797","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Granulomatous Mastitis Is Not as Benign as You Might Think: What Doctors Need to Know about the Lived Experience of People with This Rare Disease.","authors":"Mary McNaughton-Cassill, Joseph Torres, Sandra Pahl, Carolyn Cassill","doi":"10.1159/000544888","DOIUrl":"10.1159/000544888","url":null,"abstract":"<p><strong>Introduction: </strong>Granulomatous mastitis (GM) is a rare, benign disease characterized by painful inflammation, and abscesses typically on only one breast. Treatments include antibiotics, steroid treatments, and surgery, but there is no cure. The current study was designed to assess patient perceptions of living with the disease and what they would like physicians to know about their needs.</p><p><strong>Methods: </strong>The advent of the internet has enabled patients with rare conditions to reach out to support each other. Participants on a GM patient only Facebook site were asked if they would be willing to complete an anonymous survey regarding their experiences living with the disease. They completed a demographic survey, as well as measures of their pain and discomfort, psychological state, and social support.</p><p><strong>Results: </strong>The results indicated that patients with GM believe they need more help managing their pain discomfort and fatigue. They also report significant levels of depression and anxiety suggesting that they could also benefit from more psychological support.</p><p><strong>Discussion: </strong>Living with this painful, disfiguring disease for which there is no cure has a negative impact on people's mental and physical well-being. Practitioners who treat people with GM should consider providing their patients with specific pain management options, strategies for coping with fatigue and referrals to mental health practitioners who specialize in coping with chronic disease. Such efforts would help improve patient's quality of life and ability to cope with this \"benign\" but life altering disease.</p>","PeriodicalId":9310,"journal":{"name":"Breast Care","volume":"20 4","pages":"221-227"},"PeriodicalIF":2.1,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12377797/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144943845","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Risk of Cardiovascular Disease following Aromatase Inhibitor Therapy for Breast Cancer in Postmenopausal Women: A Systematic Review and Meta-Analysis.","authors":"Elijah Berbari, Arsalan Anees, Rajneesh Kaur, Femi E Ayeni, Senarath Edirimanne","doi":"10.1159/000546089","DOIUrl":"10.1159/000546089","url":null,"abstract":"<p><strong>Background: </strong>More women are recovering and living longer lives due to advancement in breast cancer therapies. Aromatase inhibitors (AIs) are one form of endocrine therapy for breast cancer that may have an impact on the risk of developing cardiovascular diseases later in life. This study investigated whether AI therapy for breast cancer in postmenopausal women increases the risk of developing cardiovascular disease in comparison with tamoxifen therapy or no hormonal therapy.</p><p><strong>Methods: </strong>Comparisons were made between tamoxifen and no hormonal therapy using PRISMA guidelines. We searched publicly available databases for studies including postmenopausal women who underwent AI therapy for breast cancer investigating the risk ratio of specific cardiovascular outcomes and cardiovascular death.</p><p><strong>Results: </strong>There was a significant increase in the risk of ischaemic heart disease (RR 1.59, 95% CI: 1.25-2.02, <i>p</i> < 0.05), myocardial infarction (RR 1.50, 95% CI: 1.13-1.99, <i>p</i> < 0.05), heart failure (RR 1.63, 95% CI: 1.14-2.32, <i>p</i> < 0.05), and other cardiovascular events (RR 1.26, 95% CI: 1.12-1.40, <i>p</i> < 0.05) in the AI group when compared to tamoxifen. However, there was a significant decrease in the risk of myocardial infarction (RR 0.77, 95% CI: 0.65-0.90, <i>p</i> < 0.05) in the AI group when compared to no hormonal treatment.</p><p><strong>Conclusion: </strong>There is an increased risk of cardiovascular disease for AI therapy in comparison to tamoxifen therapy. However, further research is needed to establish the cardiovascular risk of AIs when compared to no hormonal therapy. Prognosis and survival of patients should be an important consideration in choosing between tamoxifen and AI therapy among patients receiving treatment for breast cancer. Regular monitoring is essential to facilitate personalized approaches aimed at mitigating the risk of cardiovascular toxicity.</p>","PeriodicalId":9310,"journal":{"name":"Breast Care","volume":" ","pages":""},"PeriodicalIF":2.0,"publicationDate":"2025-06-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12259065/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144641867","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Development and Validation of a Predictive Model for Sentinel Lymph Node Biopsy Exemption in Ductal Carcinoma in situ Patients.","authors":"Zhihong Xu, Dan Tao, Qihua Jiang, Wensong Wei, Qian Ma","doi":"10.1159/000546885","DOIUrl":"10.1159/000546885","url":null,"abstract":"<p><strong>Introduction: </strong>There is no uniform standard on whether total mastectomy for ductal carcinoma in situ (DCIS) can exempt sentinel lymph node biopsy (SLNB). This study attempts to find the risk factors for the underestimation of DCIS pathology and establish the corresponding prediction model to screen suitable DCIS patients for exemption from SLNB.</p><p><strong>Methods: </strong>A total of 826 patients with DCIS met the inclusion criteria. Logistic regression identified lesion size, Ki67, estrogen receptor (ER) status, human epidermal growth factor receptor 2 (HER2) status, histological grade, and diagnostic method as independent predictors of pathological underestimation (<i>p</i> < 0.05). Based on these variables, a predictive model was developed: <i>p</i> = 0.354 × lesion size + 0.017 × Ki67 + 1.186 × ER - 2.501 × diagnosis method (1) - 1.575 × diagnosis method (2) - 0.050 × HER2 (1) - 1.578 × HER2 (2) + 1.160 × grade (1) + 1.497 × grade (2) - 2.418 (if age <50) - 0.156 × 1 (if age >50). The model showed good performance with a sensitivity of 79.2%, specificity of 73.8%, and overall accuracy of 76.2%. The area under the ROC curve (AUC) was 0.856 (95% confidence interval: 0.831-0.881, <i>p</i> < 0.001). Subgroup analyses indicated that age, presence of mass, ER, HER2, tumor grade, and histological grade significantly affected model performance (AUC = 0.787; sensitivity = 0.695; specificity = 0.753). Stratified analysis showed higher sensitivity in patients <50 years (0.840 vs. 0.656) and higher AUC in ER-positive cases (0.865). In HER2-based analysis, only the presence of a mass remained significant. Mass-based analysis revealed all variables except age were significant, with a higher AUC in patients without a mass (0.784 vs. 0.727).</p><p><strong>Conclusion: </strong>This study developed a predictive model based on lesion size, Ki67, ER status, HER2 status, histological grade, and diagnostic method to assess the risk of pathological underestimation in DCIS. The model demonstrated good predictive performance (AUC = 0.856) with high sensitivity and specificity, indicating its potential clinical utility. Subgroup analyses revealed that factors such as age, presence of a mass, and ER status influenced model performance, with particularly better accuracy observed in patients under 50 and those with ER-positive tumors. This model may serve as a useful tool to support clinical decision-making, especially in preoperative evaluation of invasive potential in DCIS patients.</p>","PeriodicalId":9310,"journal":{"name":"Breast Care","volume":" ","pages":""},"PeriodicalIF":2.0,"publicationDate":"2025-06-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12274069/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144673949","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Using Virtual Therapy for Lymphedema and Disability Post-Mastectomy: Meta-Analysis with Systematic Review.","authors":"Islam Bani Mohammad, Muayyad Ahmad","doi":"10.1159/000546605","DOIUrl":"10.1159/000546605","url":null,"abstract":"<p><strong>Introduction: </strong>This review and meta-analysis aimed to examine the effects of virtual reality (VR) therapy on lymphedema and disability management in post-mastectomy breast cancer patients, following PRISMA protocol.</p><p><strong>Methods: </strong>Databases were extensively searched, including Wiley Online Library, ProQuest, MEDLINE, CINAHL, Google Scholar, Science Direct, and SAGE Journals, covering studies from January 2016 to August 2024. This review was reported according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines.</p><p><strong>Results: </strong>Nine studies met the inclusion criteria. The findings indicate VR therapy effectively reduces post-mastectomy lymphedema and aids upper limb disability rehabilitation, with sessions lasting 10-50 min. The meta-analysis statistics showed a significant decrease in disability, measured by the disability of the arm, shoulder, and hand (DASH) scale, with an effect size of -0.931 (<i>Z</i> score = -2.713, <i>p</i> = 0.007) and a 95% confidence interval of -1.604 to -0.259.</p><p><strong>Conclusions: </strong>These results strongly support VR's efficacy in managing lymphedema and disability, recommending its integration into routine care at oncology centers and hospitals. This article explains compelling evidence that VR is effective in helping patients with lymphedema manage their disabilities. Rehabilitation programs using VR after mastectomy should be incorporated into the daily care in oncology centers and hospitals. Further interventional studies are needed to strengthen evidence and refine VRs clinical application.</p>","PeriodicalId":9310,"journal":{"name":"Breast Care","volume":" ","pages":""},"PeriodicalIF":2.0,"publicationDate":"2025-06-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12240588/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144607370","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of Safety of Elacestrant in Patients with Breast Cancer: Insights from Food and Drug Administration Adverse Event Reporting System Database Analysis.","authors":"Tailong Lv, Wenkai Bao, Shouqiang Chen","doi":"10.1159/000546678","DOIUrl":"10.1159/000546678","url":null,"abstract":"<p><strong>Introduction: </strong>This study aims to evaluate the safety profile of elacestrant in real-world settings using data from the FDA adverse event (AE) reporting system (FAERS) database, offering insights to inform clinical use.</p><p><strong>Methods: </strong>Data are collected from the FAERS database spanning the first quarter of 2023 through the third quarter of 2024. AEs associated with elacestrant are identified using reporting odds ratio, proportional reporting ratio, Bayesian confidence propagation neural network, and multinomial gamma Poisson shrinkageanalyses. The temporal distribution of AEs is assessed using Weibull distribution to evaluate the drug's safety comprehensively.</p><p><strong>Results: </strong>Reports of 6,476 AEs with elacestrant as the primary suspect drug are identified, spanning 27 organ systems. A total of 53 preferred terms signal are detected across four algorithms, including known adverse reactions such as nausea, vomiting, fatigue, elevated blood cholesterol, and musculoskeletal pain. Potential new AEs, including pathological fractures, gastroesophageal reflux disease, hypokalemia, lymphedema, and dehydration, are also identified. The median onset time for elacestrant-related AEs is 44 days, with most events occurring within the first month of treatment.</p><p><strong>Conclusion: </strong>This study offers real-world insights into elacestrant usage, confirming known adverse reactions and identifying previously unreported events. These findings provide valuable guidance for clinicians in minimizing drug risks during treatment.</p>","PeriodicalId":9310,"journal":{"name":"Breast Care","volume":" ","pages":""},"PeriodicalIF":2.0,"publicationDate":"2025-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12215442/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144559279","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of Local Recurrence Outcomes between Breast Conservation Therapy and Mastectomy for the Treatment of Breast Cancer among Young Women: A Systematic Review and Meta-Analysis.","authors":"Yiming Sun, Feng Zhang, Qi Guo, Xiaowen Ma","doi":"10.1159/000546783","DOIUrl":"10.1159/000546783","url":null,"abstract":"<p><strong>Background: </strong>Recent clinical trials comparing local recurrence rates in young breast cancer (BC) patients after breast-conserving therapy (BCT) versus mastectomy are limited. The local recurrence (LR) rate in young BC patients is notably higher than in other age groups, whether the recurrence rates after the two surgical options are comparable remains unclear. This meta-analysis aimed to assess the safety of BCT and mastectomy for young age BC patients by comparing LR rates between the two procedures.</p><p><strong>Methods: </strong>We conducted a systematic search of four electronic databases (Medline, PubMed, Cochrane Library, and Web of Science) for relevant studies comparing LR rates in BC patients aged 40 years or younger who were treated with BCT or mastectomy. Studies that met the inclusion criteria were synthesized using a random-effects model, with a primary focus on LR rates. Sensitivity analyses and meta-regression were performed to evaluate bias and heterogeneity, ensuring a thorough assessment of the available evidence.</p><p><strong>Results: </strong>Among the 2,936 studies screened, 10 studies encompassing 9,215 patients were included, with 5,236 undergoing BCT and 5,803 undergoing mastectomy. The summary odds ratio (OR) indicated a significantly greater risk of LR for BCT compared to mastectomy among young BC patients (OR = 1.48; 95% CI: 1.12-1.96). In subgroup analysis, the BCT group exhibited a higher 5-year LR rate (OR = 1.67; 95% CI: 1.13-2.46) compared to the mastectomy group. This trend persisted across tumor stages, with the BCT group showing an increased LR risk in both the T1-2 (OR = 1.84; 95% CI: 1.44-2.36) and T1-4 (OR = 1.74, 95% CI: 1.50-2.03) stages. Nodal status analysis indicated a higher LR risk for BCT in the N0-1 (OR = 2.549, 95% CI: 1.79-3.46) stages. Among very young women (aged ≤35), the difference in LR rates between BCT and mastectomy was even more pronounced (OR = 2.04, 95% CI: 1.47-2.82).</p><p><strong>Conclusion: </strong>Our meta-analysis found that young BC patients undergoing BCT had a significantly higher risk of LR, with a 48% increased risk compared to those who underwent mastectomy (OR = 1.48; 95% CI: 1.12-1.96). This difference was even more pronounced in patients aged 35 years or younger. While the elevated LR risk with BCT in young patients is well documented, individualized treatment planning should weigh this against potential survival advantages and quality-of-life preservation.</p>","PeriodicalId":9310,"journal":{"name":"Breast Care","volume":" ","pages":""},"PeriodicalIF":2.0,"publicationDate":"2025-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12234014/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144590513","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of Patient Satisfaction and Quality of Life Using the BREAST-Q Questionnaire in Oncoplastic Breast-Conserving Surgery Techniques for Centrally Located Breast Cancer.","authors":"Halit Özgül, Gülşah Çelik, Remzi Can Çakir, Ömer Çelik, Ali Çelik","doi":"10.1159/000544114","DOIUrl":"10.1159/000544114","url":null,"abstract":"<p><strong>Introduction: </strong>This study aimed to retrospectively compare the impact of level-2 oncoplastic techniques - doughnut, lateral, vertical, and racket mastopexy - on patient satisfaction and quality of life in centrally located breast cancer surgery, using the BREAST-Q questionnaire.</p><p><strong>Methods: </strong>This study included patients aged 18-65 who underwent oncoplastic surgery for centrally located breast tumors at a teaching hospital between January 2021 and August 2024. The BREAST-Q questionnaire, which assesses satisfaction with the breast, psychosocial well-being, and sexual health, was administered at least 3 months post-surgery and radiotherapy. Demographic and clinical data were collected from the patient records.</p><p><strong>Results: </strong>Among the 142 patients included in the study, 90 underwent doughnut mastopexy, while 52 received other techniques. The BREAST-Q scores indicated higher satisfaction with breasts (92.28%), psychosocial well-being (87.41%), and sexual well-being (86.39%) in the doughnut mastopexy group compared to the other techniques (<i>p</i> < 0.001).</p><p><strong>Conclusions: </strong>Doughnut mastopexy yielded better outcomes than other techniques, likely because of minimal scarring, reduced need for contralateral procedures, and improved aesthetic results. These findings suggest that this technique offers superior patient satisfaction for centrally located breast tumors.</p>","PeriodicalId":9310,"journal":{"name":"Breast Care","volume":"20 3","pages":"145-153"},"PeriodicalIF":2.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12180785/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144474050","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pyoderma Gangrenosum of the Breast: A Diagnostic Challenge.","authors":"Joaquim Marcoval, Clara Muntaner-Virgili, Júlia Boronat-Cucarull, Marta Gangonells-Dols, Alvaro Lagos-Tapia","doi":"10.1159/000544905","DOIUrl":"10.1159/000544905","url":null,"abstract":"<p><strong>Introduction: </strong>Pyoderma gangrenosum (PG) is a rare, noninfectious neutrophilic dermatosis usually located in the legs. PG of the breast is infrequent and may be a diagnostic challenge. Our objective was to review our patients with breast PG in order to analyse their clinical features.</p><p><strong>Methods: </strong>Patients diagnosed with PG involving the breast in Bellvitge University Hospital (Barcelona, Spain) between 2000 and 2023 were included in the study. Medical charts were retrospectively reviewed to obtain clinical data.</p><p><strong>Results: </strong>Ten patients were diagnosed with breast PG (10 women aged between 30 and 63 years, median 49.5). Evolution time at diagnosis ranged between 4 days and 7 months. In all cases, PG lesions were painful. All patients presented ulcerated lesions. In 2 cases, nodular abscess-like lesions and cribriform scars were also observed. The nipple was involved in 4 cases. Two patients had underlying diseases recognized as frequently associated with PG (ulcerative colitis and rheumatoid arthritis). Seven patients had a previous breast surgery that was considered related to PG (removal of breast carcinoma with breast reconstruction in 6 cases and breast reduction in one). The diagnosis of postsurgical breast PG was delayed in 6 patients by between 3 and 7 months. One patent developed radiation therapy induced pathergy after healing of postsurgical PG.</p><p><strong>Conclusion: </strong>The most common triggering factor for breast PG in our study was reconstruction following surgery for breast carcinoma. Medical professionals who treat breast diseases should be aware of this disease in order to lessen diagnostic delay.</p>","PeriodicalId":9310,"journal":{"name":"Breast Care","volume":"20 3","pages":"182-188"},"PeriodicalIF":2.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12180801/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144474051","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}